Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOST MenB Study
ACTRN12625001444471Phase 4Not yet recruiting
- Sponsor
- University of Adelaide
- Start
- Jan 2026
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of meningococcal group B vaccine in meningococcal disease and gonorrhea (2 arms), sponsored by University of Adelaide. Primary endpoints: PorA seroprotection at 12 months after dose 2 and Gonococcal indicator strain immunity at 12 months after dose 2. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal diseasegonorrhea
Beyond the preview
Go deeper on ACTRN12625001444471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001444471.